What if atrial fibrillation (AF) turned out to be a marker of risk for cardioembolic stroke but not necessarily the direct cause of culprit thrombi? Patients with embolic stroke of undetermined source ...
When it comes to handling patients with an embolic stroke of undetermined source (ESUS), which comes with high cardiovascular risk, it’s important to take a more holistic view of the situation rather ...
Rivaroxaban is no better than aspirin for the secondary prevention of stroke in patients with a prior embolic stroke of undetermined source (ESUS), and leads to more bleeding, according to results ...
Bayer and Johnson & Johnson’s Janssen Research & Development have acknowledged that their Xarelto ® (rivaroxaban) has failed a Phase III trial assessing the blockbuster anticoagulant in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results